Physician profile
John A Anderson
NPI 1740394790
$23,275.25
in general payments reported to CMS, 2019-2025
10 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $226 · 2021: $192 · 2022: $109 · 2023: $448 · 2024: $5,551 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $3,506 · Food and Beverage: $2,524 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,150.00 |
| Travel and Lodging | $3,505.91 |
| Food and Beverage | $2,524.28 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21,821.34 | 2024-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $801.97 | 2019-2024 | Xarelto, Spravato |
| Genentech USA, INC. | $261.73 | 2019-2023 | Xolair |
| Novo Nordisk INC | $89.47 | 2020 | |
| Abbvie INC. | $75.43 | 2021-2022 | |
| Amgen INC. | $62.83 | 2019 | |
| Allergan, INC. | $52.99 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $52.33 | 2023-2024 | Dupixent |
| Stryker Corporation | $40.33 | 2024 | Hydroset, Axsos, Pangea |
| Astrazeneca Pharmaceuticals LP | $16.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.